Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Seres Therapeutics, Inc.
< Previous
1
2
3
Next >
Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection
June 05, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces Receipt of $125 Million Milestone From Nestlé Health Science Following FDA Approval of VOWST™
May 30, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 09, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome
May 09, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting
May 08, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023
May 05, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces $250 Million Debt Financing with Oaktree
April 27, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 07, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
March 09, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 07, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
February 28, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
February 14, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
February 08, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
January 05, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
November 22, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 02, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
October 27, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
October 26, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
October 23, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
October 19, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
October 12, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
September 08, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
September 07, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Tickers
MCRB
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.